Processa Pharmaceuticals, Inc. (PCSA)
USD 0.94
(-6.67%)
USD 0.94
(-6.67%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 222.00 | 27.52 Million | 12.13 Million | 15.13 Million | 877.89 Thousand | 630.09 Thousand |
| Gross Profit | -222.00 | -27.52 Million | -12.13 Million | -15.13 Million | -877.89 Thousand | -630.09 Thousand |
| Operating Expenses | 11.45 Million | 20.25 Million | 11.56 Million | 6.43 Million | 3.93 Million | 4.52 Million |
| Selling, General and Administrative Expenses | 5.65 Million | 8.76 Million | 4.68 Million | 3.26 Million | 1.61 Million | 1.43 Million |
| Research and Development Expenses | 5.79 Million | 11.49 Million | 6.87 Million | 3.17 Million | 2.32 Million | 3.08 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 11.45 Million | 20.25 Million | 11.56 Million | 6.43 Million | 3.93 Million | 4.52 Million |
| Operating Income | -11.45 Million | -27.52 Million | -12.13 Million | -15.13 Million | -3.93 Million | -4.52 Million |
| Interest Expense | - | - | 362.00 | 281.12 Thousand | 36.65 Thousand | 161.2 Thousand |
| Income Tax Expense | - | 27.42 Million | -530.61 Thousand | -1 Million | -602.71 Thousand | -902.8 Thousand |
| Earnings before Tax | -11.12 Million | -27.42 Million | -11.95 Million | -15.41 Million | -3.96 Million | -4.66 Million |
| Net Income | -11.12 Million | -54.84 Million | -11.42 Million | -14.41 Million | -3.35 Million | -3.76 Million |
| Earnings Per Share Basic | -8.48 | -68.00 | -15.00 | -38.40 | -12.17 | -14.20 |
| Earnings Per Share Diluted | -8.48 | -68.00 | -15.00 | -38.40 | -12.17 | -14.20 |
| Weighted Average Shares Outstanding | 1.31 Million | 805.46 Thousand | 765.97 Thousand | 374.98 Thousand | 275.86 Thousand | 266.6 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 1.31 Million | 805.46 Thousand | 765.97 Thousand | 374.98 Thousand | 275.86 Thousand | 266.6 Thousand |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -11.45 Million | -19.46 Million | -11.08 Million | -5.63 Million | -3.04 Million | -3.87 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 3.42 Million | 139.00 | 2.8 Million | 140.00 | 222.00 | 2.16 Million |
| Gross Profit | -3.42 Million | -139.00 | -2.8 Million | -140.00 | -222.00 | -2.16 Million |
| Operating Expenses | 3.42 Million | 3.08 Million | 2.8 Million | 2.46 Million | 11.45 Million | 2.16 Million |
| Selling, General and Administrative Expenses | 1.13 Million | 1.35 Million | 1.27 Million | 1.14 Million | - | 1.01 Million |
| Research and Development Expenses | 2.28 Million | 1.73 Million | 1.53 Million | 1.32 Million | - | 1.15 Million |
| Other Expenses | - | 71.69 Thousand | - | -185.36 Thousand | - | - |
| Cost and Expenses | 6.84 Million | 3.08 Million | 5.61 Million | 2.46 Million | 11.45 Million | 2.16 Million |
| Operating Income | -6.84 Million | -3.08 Million | -5.61 Million | -2.46 Million | -11.45 Million | -2.16 Million |
| Interest Expense | - | - | - | 4.18 Million | - | - |
| Income Tax Expense | -203.00 | 1.00 | -139.00 | 2.04 Million | -2.00 | 2.16 Million |
| Earnings before Tax | -3.38 Million | -3.01 Million | -2.72 Million | -2.4 Million | -11.12 Million | -2.08 Million |
| Net Income | -3.38 Million | -3.01 Million | -2.72 Million | -2.4 Million | -11.12 Million | -2.08 Million |
| Earnings Per Share Basic | -1.03 | -1.01 | -1.10 | -1.30 | - | -1.50 |
| Earnings Per Share Diluted | -1.03 | -1.01 | -1.10 | -1.30 | - | -1.50 |
| Weighted Average Shares Outstanding | 3.27 Million | 2.98 Million | 2.46 Million | 1.88 Million | 13.11 Million | 1.35 Million |
| Weighted Average Shares Outstanding (Diluted) | 3.27 Million | 2.98 Million | 2.46 Million | 1.88 Million | 13.11 Million | 1.35 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -6.84 Million | -3.08 Million | -5.61 Million | -2.46 Million | - | -2.16 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
0SAY
KOHINOOR
KLINIQ
XPG
002117
TIIL